Organisms | Evidence |
---|---|
Chlorocebus aethiops (grivet) |
Gene Symbol | Donor | Acceptor | Reducing terminal(Acceptor) | Product | Reducing terminal(Product) | Reference |
---|---|---|---|---|---|---|
C1GALT1 | (not applicable) |
|
Ser/Thr |
|
Ser/Thr | |
ST6GALNAC1 | CMP-Neu5Ac |
|
O-glycan Synthesis |
|
O-glycan Synthesis | |
ST6GALNAC1 | CMP-Neu5Ac |
|
Ser/Thr |
|
Ser/Thr | |
B3GNT6 | UDP-GlcNAc |
|
[alpha]-pNP |
|
[alpha]-pNP |
Gene Symbol | Donor | Acceptor | Reducing terminal(Acceptor) | Product | Reducing terminal(Product) | Reference |
---|---|---|---|---|---|---|
C1GALT1 | (not applicable) |
|
Ser/Thr |
|
Ser/Thr | |
ST6GALNAC1 | CMP-Neu5Ac |
|
[Ala-Thr(*)-Ala]2-7 |
|
[Ala-Thr(*)-Ala]2-7 | |
ST6GALNAC1 | CMP-Neu5Ac |
|
O-glycan Synthesis |
|
O-glycan Synthesis | |
ST6GALNAC1 | CMP-Neu5Ac |
|
Ser/Thr |
|
Ser/Thr | |
ST6GALNAC4 | CMP-Neu5Ac |
|
benzyl |
|
benzyl |
Gene Symbol | Donor | Acceptor | Reducing terminal(Acceptor) | Reference |
---|---|---|---|---|
ST8SIA6 | CMP-Neu5Ac |
|
||
ST6GALNAC2 | CMP-Neu5Ac |
|
para-nitrophenol | |
ST6GAL2 | CMP-Neu5Ac |
|
para-nitrophenol | |
ST6GAL1 | CMP-Neu5Ac |
|
para-nitrophenol | |
ST6GALNAC3 | CMP-Neu5Ac |
|
Ser/Thr |
Pathway Name | Organism |
---|---|
E.coli O101 | Escherichia coli |
E.coli O103 | Escherichia coli |
E.coli O107 | Escherichia coli |
E.coli O112ab | Escherichia coli |
E.coli O112ac | Escherichia coli |
E.coli O116 | Escherichia coli |
E.coli O117 | Escherichia coli |
E.coli O125ab | Escherichia coli |
E.coli O127 | Escherichia coli |
E.coli O128ab-H27 | Escherichia coli |
RES 1b:a-dgal-HEX-1:5 2s:n-acetyl LIN 1:1d(2+1)2n
PubMed ID | Title | First Author | Publication Date | Source |
---|---|---|---|---|
38348876 | A combinatorial approach for achieving CNS-selective RNAi | Ferguson CM | 2024 Feb 13 |
|
38227794 | Safety and Tolerability of GalNAc3-Conjugated Antisense Drugs Compared to the Same-Sequence 2′-O-Methoxyethyl-Modified Antisense Drugs: Results from an Integrated Assessment of Phase 1 Clinical Trial Data | Baker BF | 2024 Feb 01 |
|
39177802 | Givosiran for the Treatment of Pediatric Acute Intermittent Porphyria | Bujold KE | 2024 Aug 22 |
|
39126245 | O-GlcNAcylation determines the function of the key O-GalNAc glycosyltransferase C1GalT1 in bladder cancer | Jiang Y | 2024 Aug 01 |
|
38667801 | Chemical Synthesis of Fucosylated Chondroitin Sulfate Tetrasaccharide with Fucosyl Branch at the 6-OH of GalNAc Residue | Lv C | 2024 Apr 19 |
|
38479165 | Research progress on asialoglycoprotein receptor-targeted radiotracers designed for hepatic nuclear medicine imaging | Hua Y | 2024 Apr 05 |
|
38570436 | Cross-Reactive Polyclonal Antibodies Raised Against GalNAc-Conjugated siRNA Recognize Mostly the GalNAc Moiety | Ballman KK | 2024 Apr 03 |
|
38401583 | Deficiency of polypeptide N-acetylgalactosamine transferase 9 contributes to a risk for Parkinson's disease via mitochondrial dysfunctions | Peng Y | 2024 Apr |
|
38708485 | Recovery of chronic motor neuropathy due to acute intermittent porphyria after givosiran treatment in a young boy: a case report | Mazzoli M | 2024 Apr |
|
38995536 | Integrating HexNAcQuest with Glycoproteomics Data Analysis Software to Distinguish HexNAc Isomers on Peptides | Hou C | 2024 |
|
Title | Authors | Source | Publication Date | PubMed ID |
---|---|---|---|---|
GALNTs: master regulators of metastasis-associated epithelial-mesenchymal transition (EMT)? |
|
Glycobiology | 2022 Jun 13 | 35312770 |
The first crystal structure of a family 129 glycoside hydrolase from a probiotic bacterium reveals critical residues and metal cofactors. |
|
J Biol Chem | 2017 Jul 21 | 28546425 |
The Quest for Anticancer Vaccines: Deciphering the Fine-Epitope Specificity of Cancer-Related Monoclonal Antibodies by Combining Microarray Screening and Saturation Transfer Difference NMR. |
|
J Am Chem Soc | 2015 Oct 7 | 26366611 |
Single molecule study of heterotypic interactions between mucins possessing the Tn cancer antigen. |
|
Glycobiology | 2015 May | 25527429 |
Loss of Core 1-derived O-Glycans Decreases Breast Cancer Development in Mice. |
|
J Biol Chem | 2015 Aug 14 | 26124270 |
GlyCosmos is a member of the GlySpace Alliance together with GlyGen and Glycomics@ExPASy.
Supported by JST NBDC Grant Number JPMJND2204
Partly supported by NIH Common Fund Grant #1U01GM125267-01
This work is licensed under Creative Commons Attribution 4.0 International
GlyCosmos Portal v4.2.1
Last updated: April 7, 2025